Adicet Bio (ACET) Stock Price, News & Analysis

Company Overview

Adicet Bio, Inc. (NASDAQ: ACET) is a clinical‐stage biotechnology company specializing in the development of off‐the‐shelf, allogeneic gamma delta (γδ) T cell therapies for oncology and autoimmune disorders. The company’s proprietary platform enables the genetic engineering of γδ T cells with chimeric antigen receptors (CARs) and other molecular modifications to enhance tumor targeting, expansion, and persistence. By leveraging the innate tumor-recognition properties of γδ T cells, Adicet seeks to overcome the manufacturing and safety challenges associated with autologous cell therapies.

Adicet’s lead product candidate, ADI-001, is a CAR‐engineered allogeneic γδ T cell therapy directed against CD20 for the treatment of relapsed or refractory B-cell malignancies. The company also has a pipeline of next-generation candidates targeting solid tumors and autoimmune indications, each built on its platform’s ability to combine γδ T cell receptors with co-stimulatory and cytokine support elements. Early‐stage clinical studies are under way to evaluate safety, tolerability, and preliminary efficacy in multiple patient populations.

Founded in 2016 and headquartered in South San Francisco, California, Adicet Bio maintains operations in both the U.S. and Suzhou, China, where it conducts process development and manufacturing. The company completed its initial public offering in February 2020 and has since advanced its platform through strategic collaborations and internal research programs. Under the leadership of Chief Executive Officer Michelle Dipp, Adicet continues to expand its cell therapy capabilities and to position its allogeneic γδ T cell technology as a potential new standard for scalable, off‐the‐shelf immunotherapies.

Key Stats

• Today's Range: $8.78 to $9.25
• 50-Day Range: $7.79 to $9.49
• 52-Week Range: $6.01 to $17.44
• Volume: 52,623 shs
• Average Volume: 126,031 shs
• Market Capitalization: $83.40 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $46.80
• Consensus Rating: Moderate Buy

Adicet Bio Stock Analysis - MarketRank™

Adicet Bio scored higher than 81% of companies evaluated by MarketBeat, and ranked 146th out of 920 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.8 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Adicet Bio has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 1 strong buy rating, 5 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Adicet Bio has a consensus price target of $46.80, representing about 427.0% upside from its current price of $8.88.

Amount of Analyst Coverage

Adicet Bio has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Adicet Bio are expected to grow in the coming year, from ($6.76) to ($5.64) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Adicet Bio is -0.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Adicet Bio is -0.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Adicet Bio has a P/B Ratio of 0.69. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.90% of the float of Adicet Bio has been sold short.

Short Interest Ratio / Days to Cover

Adicet Bio has a short interest ratio ("days to cover") of 3.17, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Adicet Bio has recently decreased by 33.92%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Adicet Bio does not currently pay a dividend.

Dividend Growth

Adicet Bio does not have a long track record of dividend growth.

News and Social Media

• Score: 3.9 / 5
• News Sentiment: 1.22

News Sentiment

Adicet Bio has a news sentiment score of 1.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.90 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Adicet Bio this week, compared to 3 articles on an average week.

Search Interest

Only 2 people have searched for ACET on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

MarketBeat Follows

3 people have added Adicet Bio to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Adicet Bio insiders have not sold or bought any company stock.

Percentage Held by Insiders

3.40% of the stock of Adicet Bio is held by insiders.

Percentage Held by Institutions

83.89% of the stock of Adicet Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/05/2026
• Today: 8/28/2026
• Next Earnings (Estimated): 11/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:ACET
• CIK: 1720580
• Web: www.aceto.com
• Phone: (650) 503-9095
• Fax: N/A
• Employees: 90
• Year Founded: 2016

Price Target and Rating

• Average Price Target for Adicet Bio: $46.80
• High Price Target: $90.00
• Low Price Target: $18.00
• Potential Upside/Downside: +425.3%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.75
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): ($11.45)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$116.80 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -74.90%
• Return on Assets: -60.87%

Debt

• Debt-to-Equity Ratio: 0.01
• Current Ratio: 6.71
• Quick Ratio: 6.71

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $12.83 per share
• Price / Book: 0.69

Miscellaneous

• Outstanding Shares: 9,360,000
• Free Float: 9,043,000
• Market Cap: $83.40 million
• Optionable: Optionable
• Beta: 1.60